Dr. Michael E. Makover is a Ny, New York based male rheumatologist who is specialized in Rheumatology. Active license number of Dr. Michael E. Makover is 104669 in New York. Dr. Michael E. Makover treat joint disease similar to orthopedists but do not perform surgeries. He diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Dr. Michael E. Makover speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
MD
Gender:
Male
Practice Address:
901 Fifth Ave., Ny, New York, 10021-4115
Phone:
212-517-5660
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1427069988
NPI Enumeration Date:
10 Aug, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Michael E. Makover are as mentioned below.
License Number
Specialization
State
Status
104669
New York
Primary
104669
Internal Medicine
New York
Secondary
104669
Rheumatology
New York
Secondary
104669
Preventive Medicine
New York
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
901 Fifth Ave., Ny, New York
Zip:
10021-4115
Phone Number:
212-517-5660
Fax Number:
--
Patients can reach Dr. Michael E. Makover at 901 Fifth Ave., Ny, New York or can call to book an appointment on 212-517-5660. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.